Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...
In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
Vertex Pharmaceuticals Incorporated (VRTX), headquartered ... Ahead of the event, analysts expect Vertex to report a profit of $3.41 per share on a diluted basis, down 4.5% from $3.57 per share ...
Also, high R&D expenses on advanced technologies ... (You can read the full research report on Vertex Pharmaceuticals here >>>) Shares of BK Technologies have outperformed the Zacks Wireless ...